Related Industry Reports:
- H1N1 (Swine Influenza) Market Assessment
- H1N1 Swine Flu Vaccine Market Review (Revenues, Forecasts, Lessons for Future Pandemic Vaccines)
- Influenza Vaccines - Pipeline Assessment and Market Forecasts to 2017
- Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
- RNAi - technologies, markets and companies
Effective siRNAs inhibit the replication of novel influenza A (H1N1) virus.
Antiviral research 2010 Jan 7; In press
Zhiqiang W, Yaowu Y, Fan Y, Jian Y, Yongfeng H, Lina Z, Jianwei W, Qi J
State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing 100176, PR China.
In March and April 2009, an entirely novel influenza A (H1N1) virus (NIAV) emerged in Mexico and the USA. During the subsequent months, the virus rapidly spread all over the world by person-to-person transmission. In this report, RNA interference (RNAi) was used as an antiviral agent to inhibit NIAV replication in A549 cells. Ten small interfering RNAs (siRNAs) targeting extremely conserved regions among multiple NIAV genomes could effectively block the replication of NIAV strain A/Beijing/01/2009 (H1N1) in A549 cells. This study may be useful to confront the sudden emergence of NIAV infection.